Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose intravenous silibinin as add-on to telaprevir-based triple therapy in cirrhotic HCV GT1 null responders
DRKS00005455Phase 2Terminated
- Sponsor
- Leipzig University
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Legalon SIL in hepatitis C virus infection and Cirrhosis, sponsored by Leipzig University. Started Mar 2015; status: terminated.
02
Drugs
Legalon SIL
03
Conditions
hepatitis C virus infectionCirrhosis
Beyond the preview
Go deeper on DRKS00005455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00005455.